The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 10, 2021

Primary Completion Date

October 20, 2021

Study Completion Date

November 1, 2021

Conditions
COVID-19 Pneumonia
Interventions
BIOLOGICAL

Bacillus subtilis

Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.

Trial Locations (1)

Unknown

Zentrogene Bioscience Laboratory Ltd, Hong Kong

All Listed Sponsors
lead

DreamTec Research Limited

INDUSTRY